Antimicrobial peptides (the alternate plural tag) covers the same field as #antimicrobial-peptide. Coverage runs across Peptilogics' biofilm work, Fedora's FPI-2119 lactivicin, Longhorn Vaccines' DRG5-BD11, and the HMD-AMP discovery platform from HLB Innovation.
The academic side has been productive. Groups at Birmingham (PEPITEM), Oxford, and others have published on AMP discovery, MRSA, and biofilm penetration. Nature Biomedical Engineering and Nature Biotechnology AMP papers continue to surface AI-discovered scaffolds.
For the singular form, see #antimicrobial-peptide. For the policy and resistance context, see #amr and #antibiotic-resistance.
Researchers at Houston Methodist Hospital and the National and Kapodistrian University of Athens reported in Frontiers in Microbiology on October 19, 2026 that CIT8, a 13-amino-acid antimicrobial peptide previously tuned by machine learning against MRSA, also kills drug-resistant Gram-negative bacteria. It inhibited 15 of 16 Acinetobacter baumannii strains at 4 µg/mL, including carbapenem-resistant clinical isolates, and at five times that dose cut about 50 million bacteria per mL to undetectable levels within 15 minutes by breaking their membranes. CIT8 and a mirror-image version also disrupted biofilms with relatively low toxicity to human cells; the work is in the lab.
Researchers at Shanghai Jiao Tong University reported in Nature Communications on October 17, 2026 a deep-learning model that designs antimicrobial lipopeptides, peptides with a fatty-acid tail, by accounting for how the tail changes activity. Starting from 2,657 bacterial peptide sequences mined from 96,911 genomes, the model screened 6,197 virtual lipopeptides; of 46 the team made, 44 killed bacteria, a 95.7% hit rate. The lead, LP630, worked against Gram-positive and Gram-negative bacteria and mycobacteria and treated infected wounds in mice.
Weizmann Institute of Science researchers reported in the Journal of Medicinal Chemistry on October 17, 2026 that adding isopeptide bonds and fatty-acid tails to antimicrobial peptides produced lipo-isopeptides that resisted breakdown by protein-cutting enzymes and were most active against the yeast Candida albicans. The lead compound, C8-Amp1EP, was non-toxic in their tests, reduced fungal attachment and biofilm formation when coated on surfaces and cells, disrupted the fungal membrane, and was less likely than standard antifungal drugs to select for resistance during repeated exposure. The work is in the lab.
A Johns Hopkins Bloomberg School of Public Health team reported in npj Antimicrobials and Resistance on October 13, 2026 a genome survey of Anopheles gambiae, the main African malaria mosquito, that identified 36 previously uncharacterized antimicrobial peptide candidates. Lab-made versions of four, named Anolarvin, Konopsin, Sialicin, and Cryptophelin, killed or stopped a broad range of microbes, and the two found mainly in salivary glands, Sialicin and Cryptophelin, reduced the viability of Plasmodium falciparum sporozoites, the parasite stage mosquitoes inject, by about 81% and 75% in lab tests. The authors see them as leads for blocking malaria transmission.
Researchers from Dermatide Biotec in Singapore, DFSIN Biotechnology in Shanghai, and Jiangnan University reported in Scientific Reports on October 11, 2026 a cyclic antimicrobial peptide, AMCP, that killed the acne bacterium C. acnes at 0.5 µg/mL and S. aureus at 1.0 µg/mL, reduced hormone- and fatty-acid-driven oil production in skin oil-gland cells by 40.0% and 29.1%, and lowered several inflammatory signals in skin cells. A delivery mix of 2% propylene glycol and 0.1% sodium surfactin raised the peptide's passage through skin fivefold in lab tests. All results come from cells and skin-permeation models, not people.
Researchers at Zhejiang University of Technology in China and Egypt's National Research Centre reported in the Journal of Medicinal Chemistry on October 7, 2026 a deep-learning model, SMAMP, that reads peptides as full chemical structures, so it can handle unnatural amino acids and end-group changes that sequence-based models miss. Of 19 very short peptides designed with its help, 13 killed bacteria, and the model's predicted potency against E. coli tracked lab measurements (correlation 0.764). Two leads, HP-1 and HP-2, were strongly bactericidal with low toxicity to mammalian cells, led to less resistance than standard antibiotics in lab tests, protected wax moth larvae from infection, and helped wounds heal in mice.
Stanford researchers led by Eric Appel reported in the journal Matter, as described by phys.org on September 22, 2026, that they trained an AI model on known antimicrobial peptides and used it to screen 1.7 million candidate polyacrylamide polymers designed to mimic how those peptides kill bacteria. The team synthesized and tested 10 of the model's picks; all 10 performed well above expectations against E. coli, one was especially effective against biofilms, and the approach also worked against Staphylococcus aureus. Co-author Shoshana Williams called them among the most potent antimicrobial polymers ever reported. The polymers rip holes in bacterial membranes, a mechanism the researchers say makes resistance harder to evolve; clinical use remains a future goal.
Two 2026 antimicrobial peptide research programs continue to press on multidrug-resistant Staphylococcus aureus. CAMPER (a mechanistic artificial intelligence system for designing peptides that target MRSA persister cells, published 2026) generated a new class of AMPs that reach the metabolically dormant persister subpopulation that survives conventional antibiotic exposure and drives biofilm relapse. Li et al. (2026) developed RFC, a self-assembling peptide that mimics the structure and function of neutrophil extracellular traps (NETs), forming nanofibrillar networks that entrap bacteria and disrupt their membranes. Separate work published this year characterized photo-responsive amyloid nanoNETs from lysozyme-derived nanofibrils that combine antibacterial activity against MRSA with promotion of tissue regeneration under near-infrared stimulation. Synergistic combinations with existing antibiotics (nisin, indolicidin, and α-MSH analogs with β-lactams) continue to show improved anti-biofilm efficacy in vitro. The programs are still preclinical but keep antimicrobial peptides in serious development at a time when the small-molecule antibiotic pipeline remains thin.
A study in Nature Communications describes a linear antimicrobial peptide built from four D-tryptophan/D-arginine/D-lysine repeats that stays stable in the body and kills multidrug-resistant bacteria, including MRSA and Klebsiella pneumoniae. In bacterial pneumonia models, the peptide acted through membrane targeting alongside DNA binding, reactive-oxygen accumulation, and ATP depletion, showed low potential to drive resistance, and helped restore sensitivity to existing antibiotics.
A research team published in Frontiers in Pharmacology in June 2026 a machine-learning pipeline for discovering antimicrobial peptides active against Pseudomonas aeruginosa, one of the WHO's top-priority gram-negative pathogens for new antibiotic development. The model was externally validated using 124 experimentally confirmed AMPs from recent publications. Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia and bloodstream infection in immunocompromised patients, and the rise of carbapenem-resistant strains has narrowed remaining treatment options to colistin and ceftolozane-tazobactam. The paper sits in a broader 2026 ML-AMP wave that also includes 'Advances in the Application of Deep Learning for Antimicrobial Peptide Screening' (Agricultural Science and Food Processing) and an arxiv preprint on multilabel AMP classification benchmarks. AMP discovery is one of the few peptide-drug verticals advancing in parallel to GLP-1 headlines, with no commercial obesity-driven distortion of academic publication pipelines.
A review published May 19 in Drug Delivery and Translational Research analyzed nano-antimicrobial peptides (nano-AMPs) — antimicrobial peptides packaged into nanoparticle delivery systems — as a strategy to overcome the three barriers that have kept AMPs out of the clinic despite decades of promise: systemic toxicity, proteolytic instability, and manufacturing cost. The review focuses on activity against multidrug-resistant Gram-negative bacteria, the hardest antimicrobial-resistance target where the conventional-antibiotic pipeline is thinnest. Nanoparticle encapsulation can shield AMPs from protease degradation, reduce off-target toxicity by controlling release, and improve tissue targeting. The piece joins the broader 2026 AMP research wave — AI-designed peptides (ProteoGPT, CAMPER), generative-AI discovery in Nature Microbiology, and ancient-microbiome AMP mining — that is collectively maturing the antimicrobial peptide field toward clinical viability against the ESKAPE pathogens responsible for most drug-resistant infections.
A Nature Microbiology paper (published May 22) reported a generative artificial-intelligence approach for discovering antimicrobial peptides against multidrug-resistant bacteria. The method uses transfer learning to give large language models domain-specific knowledge for high-throughput mining and generation of novel AMP candidates. The work joins the 2026 AI-AMP wave — ProteoGPT's 94.4% hit rate, the CAMPER mechanistic-AI MRSA platform, ancient-microbiome AMP mining, and the May 19 nano-AMP delivery review — that is collectively moving the antimicrobial peptide field from computational prediction toward clinical candidates. The convergence matters because antimicrobial resistance is projected to cause up to 10 million deaths annually by 2050, and the conventional small-molecule antibiotic pipeline has thinned to the point where membrane-targeting peptides with low resistance-development propensity are among the most credible near-term alternatives. The generative-AI design stack plus nanoparticle delivery addresses the two historical AMP bottlenecks — discovery throughput and the toxicity/stability/manufacturing gap — in parallel.
A 2026 Nature Communications paper introduced AMPLiT — a tool for screening antimicrobial peptide candidates in metagenomic datasets — and applied it to human coprolite metagenomes (ancient stool samples). The team identified candidate AMPs from extinct gut-microbiome lineages that have functional activity against modern multidrug-resistant pathogens. The approach extends the AMP-discovery search space from contemporary microbial sequences to the much-larger reservoir of evolutionary AMPs encoded in ancient host-microbiome assemblies preserved in archaeological samples. The strategy joins the broader 2026 AI-AMP wave (ProteoGPT, CAMPER, the AI-driven AMP characterization paper in Scientific Reports) as an alternative source of novel chemistry against ESKAPE pathogens. The work positions ancient-DNA-based AMP discovery as a credible track alongside computational design.
Fadi Shehadeh, Biswajit Mishra and collaborators published CAMPER (Constraint-driven AMP Engineering with Ranking) in Nature Communications 2026, integrating machine learning with mechanistic biological features to design peptides that target MRSA persister cells. The lead candidate, WP-CAMPER1, kills S. aureus MW2 at a minimal inhibitory concentration of 4 µg/mL. A 2% topical formulation reduced bacterial burden 2.5 log10 in a murine prophylactic skin infection model; the D-enantiomer WP-CAMPER1-d achieved 1.37 log10 reduction in established biofilm infections.
A Cell Biomaterials review published April 16 maps the AI-driven antibiotic-discovery landscape across two strategy families: mining (using discriminative models on genomic/proteomic sequence libraries) and generation (using diffusion and language models to design novel synthetic peptides exceeding nature's repertoire). Companion work flagged in the review includes the University of Pennsylvania AMP-Diffusion system, which produced tens of thousands of candidate peptides — 46 prioritized, three quarters bacterial-inhibitory, and two with in vivo efficacy matching approved antibiotics in mouse infection models.
A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.
April-May 2026 produced an unusual concentration of peer-reviewed advances against antimicrobial resistance, with peptide therapeutics anchoring much of the progress. The Frontiers in Bioinformatics March 17 review documented an AI/LLM pipeline (ProteoGPT) that produced 17 active peptides out of 18 designed (94.4% hit rate) in 48 days — collapsing the traditional discovery timeline. A Nature Microbiology generative-AI approach produced novel AMPs against multidrug-resistant bacteria with anti-inflammatory effects and minimal cytotoxic risk. Other April-May 2026 breakthroughs: Houston Methodist's CAMPER engineered against MRSA, the Manchester team's alternative ligase pathway to penicillins, and the Indian Institute of Technology Roorkee antibacterial peptide-drug conjugate against NDM-1/IMP-1 metallo-beta-lactamase pathogens. The combined wave signals the peptide-design stack has matured enough to compete directly with small-molecule antibiotic development.
A Frontiers in Bioinformatics review published March 17, 2026 from Tope Abraham Ibisanmi and colleagues at UNSW Sydney documents how computational antimicrobial peptide discovery has collapsed from decades to weeks. The review covers big-data mining, molecular dynamics simulations, and AI methods that capture complex sequence-activity relationships and predict novel AMPs from genomic and metagenomic data. The headline example: one large language model approach produced 18 de novo peptides of which 17 were active (94.4% hit rate) over a 48-day discovery cycle. The framing complements the broader AMP-as-AMR-response thesis with Aifeity, the University of Bonn, and Cesar de la Fuente at Penn — and lands as Cesar de la Fuente's Penn lab launches new generative AMR molecules into ESKAPE-pathogen testing.